Patents Examined by Kimberly Ballard
  • Patent number: 10842871
    Abstract: A method for treatment of a human patient for Alzheimer's disease (AD) comprises sequentially administering multiple doses of a recombinant, fully human, anti-amyloid beta monoclonal antibody to the patient. In preferred embodiments, the antibody is administered in increasing amounts over a period of time. In preferred embodiments, the susceptibility of the patient to amyloid related imaging abnormalities (ARIA) is thereby reduced.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: November 24, 2020
    Assignee: Biogen International Neuroscience GmbH
    Inventors: James L. Ferrero, Leslie Lugene Williams, Jeffrey Joseph Sevigny
  • Patent number: 10835582
    Abstract: The present invention relates to a pharmaceutical composition for preventing and treating hearing loss. More particularly, the present invention relates to a composition including a telomerase-derived peptide, the composition being effective in the treatment and prevention of hearing loss due to an ototoxic drug. A peptide having a sequence of SEQ ID NO: 1, a peptide having 80% or more sequence homology to the sequence, or a fragment thereof, according to the present invention, has an excellent effect in the treatment and prevention of hearing loss due to an ototoxic drug.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: November 17, 2020
    Assignee: GemVaX & KAEL CO. LTD.
    Inventor: Sang Jae Kim
  • Patent number: 10836814
    Abstract: The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 17, 2020
    Assignees: YOKOHAMA CITY UNIVERSITY, CHIOME BEOSCIENCE INC.
    Inventors: Yoshio Goshima, Fumio Nakamura, Naoya Yamashita, Hidetaka Seo, Shuichi Hashimoto, Koji Murakami, Naoki Takahashi, Yukie Sasakura
  • Patent number: 10829528
    Abstract: The present invention relates to the field of disorders of the central nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that soluble amyloid precursor protein a (sAPP?) presents a particular binding site, which allows for binding to the GABABR1a receptor, thereby causing an agonistic effect through specific binding to Sushi domain 1 of GABABR1a. As a result, the frequencies of excitatory and inhibitory postsynaptic currents are reduced. Accordingly, the invention provides compounds able to interfere with the association of sAPP? with Sushi domain 1 of GABABR1a and as such with selective impairment of GABABR1sa beneficial in neurological and psychiatric disorders. The invention as well provides methods and (high content) screening assays for the production of said compounds.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: November 10, 2020
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Joris De Wit, Heather Rice, Bart De Strooper
  • Patent number: 10829547
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: November 10, 2020
    Assignees: Eisai R&D Management Co., Ltd., UCL Business LTD
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Patent number: 10823739
    Abstract: The present invention provides novel peptides, compositions, and methods for creating quantitative novel compositions, as well as methods for creating quantitative standards to calibrate analytes. These peptides, compositions, and methods enable the creation of standards and calibrators for analyzing analytes and measuring clinical biomarkers (e.g., Tau). Also provided are kits comprising the peptides or compositions described herein, for use in assays (e.g., sandwich immunoassays).
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: November 3, 2020
    Assignee: SALADAX BIOMEDICAL
    Inventors: Paul Rhyne, Adam J. Simon, Flora Berisha, Robert John Neely, Christopher J. Spedaliere, Claudio Mapelli
  • Patent number: 10821185
    Abstract: Disclosed herein are triglyceride based formulations, compositions, and methods for the treatment of otic diseases and conditions. Such triglyceride based formulations and compositions are derived from medium chain triglycerides and allow for the delivery of a variety of therapeutic agents to the outer, middle, and/or inner ear.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: November 3, 2020
    Assignee: Otonomy Inc.
    Inventors: Robert Savel, Zhanpeng Zhang, Scott Coleman, Fabrice Piu, Hong Qi
  • Patent number: 10813979
    Abstract: Methods, compositions, and kits for diagnosing or treating neurodegenerative or neuroinflammatory conditions are provided. Also provided are methods for identifying modulators of neurodegenerative or neuroinflammatory conditions.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: October 27, 2020
    Assignee: The Hong Kong University of Science and Technology
    Inventors: Kit Yu Fu, Foo Yew Liew, Nancy Yuk-Yu Ip
  • Patent number: 10800844
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 13, 2020
    Assignee: ALECTOR LLC
    Inventors: Arnon Rosenthal, Kate Monroe, Seung-Joo Lee
  • Patent number: 10802019
    Abstract: The invention relates to methods of determining whether or not an individual has or is likely to develop a neurological disease and related methods and kits.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: October 13, 2020
    Assignee: Oxford University Innovation Limited
    Inventors: Angela Vincent, Philippa Pettingill, Patrick Waters
  • Patent number: 10786536
    Abstract: Cardiac neural crest cells and methods for making and using the same to effect cardiac injury is described herein.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: September 29, 2020
    Assignee: VESTION, INC.
    Inventors: Konstantinos E. Chatzistergos, Joshua M. Hare
  • Patent number: 10786557
    Abstract: Compositions and methods useful for the treatment of neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) are disclosed.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: September 29, 2020
    Assignee: SHIRE VIROPHARMA LLC
    Inventors: Colin Broom, Jeffrey Dayno
  • Patent number: 10781420
    Abstract: The present invention provides a method for producing a human cell aggregate containing a midbrain-hindbrain boundary neural progenitor tissue, including subjecting an aggregate of human pluripotent stem cells to suspension culturing in a serum-free medium containing insulin, and treating, in the suspension culturing, the aggregate of human pluripotent stem cells or a human cell aggregate derived therefrom with a ROCK inhibitor, a TGF? signal inhibitor, and a first fibroblast growth factor. Furthermore, the human cell aggregate containing the midbrain-hindbrain boundary neural progenitor tissue is subjected to suspension culturing in a serum-free medium to induce formation of a neuroepithelial structure by neural progenitor in the neural progenitor tissue, whereby the human cell aggregate containing the cerebellar plate tissue can be obtained.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: September 22, 2020
    Assignees: RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Yoshiki Sasai, Keiko Muguruma
  • Patent number: 10780131
    Abstract: The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: September 22, 2020
    Assignee: The Regents of the University of California
    Inventors: Arnold Kriegstein, John L. R. Rubenstein, Scott C. Baraban, Arturo Alvarez-Buylla
  • Patent number: 10781421
    Abstract: The present invention pertains to a method for the generation of neurotoxin-sensitive, neuronal differentiated cells comprising the steps of: a) cultivating tumor cells which are able to differentiate into neuronal cells in a culture medium under conditions and for a time which primes said tumor cells for neuronal differentiation; and b) cultivating the tumor cells primed for neuronal differentiation of a) in a differentiation medium having an osmolality of 100 to 270 mOsm/kg, and comprising (i) B27 supplement and/or (ii) N2 supplement, for at least 3 days, thereby obtaining neurotoxin-sensitive, neuronal differentiated cells. The invention further relates to neurotoxin-sensitive, neuronal differentiated cells obtainable by the method of the invention.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: September 22, 2020
    Assignee: MERE PHARMA GmbH & CO. KGaA
    Inventors: Karl-Heinz Eisele, Kai Harting
  • Patent number: 10772969
    Abstract: The disclosure pertains to N-terminal epitopes identified in A-beta, including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: September 15, 2020
    Assignee: The University of British Columbia
    Inventors: Neil R. Cashman, Steven S. Plotkin
  • Patent number: 10752679
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: August 25, 2020
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
  • Patent number: 10730937
    Abstract: An anti-HMGB1 antibody comprising a light chain variable region comprising complementarity-determining regions or the like including amino acid sequences of SEQ ID NOs: 4 to 6, and a heavy chain variable region comprising complementarity-determining regions or the like including amino acid sequences of SEQ ID NOs: 10 to 12, or an anti-HMGB1 antibody comprising a light chain variable region or the like comprising an amino acid sequence of SEQ ID NO: 3, and a heavy chain variable region comprising an amino acid sequence or the like of SEQ ID NO: 9, and a composition for treating or preventing Alzheimer's disease, comprising the same as an active ingredient.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: August 4, 2020
    Assignee: National University Corporation Tokyo Medical and Dental University
    Inventors: Hitoshi Okazawa, Masunori Kajikawa
  • Patent number: 10729788
    Abstract: In alternative embodiments, provided are methods for increasing levels of and/or upregulating the expression of ApoA-I Binding Protein (APOA1BP, AIBP, or AI-BP) to treat, ameliorate, prevent, reverse, decrease the severity or duration of: a neuropathic pain, including an inflammation-induced neuropathic pain, a nerve or CNS inflammation, a, a post nerve injury pain, a post-surgical pain, a chemotherapeutic-induced peripheral neuropathy (CIPN) (e.g., cisplatin-induced allodynia) a neurodegeneration or neurodegenerative disease or condition, a migraine, and/or a hyperalgesia.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: August 4, 2020
    Assignee: The Regents of the University of California
    Inventors: Yury Miller, Tony L. Yaksh
  • Patent number: 10729815
    Abstract: A combined treatment for nerve injury is provided. Accordingly there is provided a composition comprising a hyaluronic acid, a laminin polypeptide, an antioxidant and an anti-gliotic agent. Also provided are matrices and hydrogels of the composition and methods of using same.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: August 4, 2020
    Assignees: Ramot at Tel-Aviv University Ltd., The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
    Inventors: Shimon Rochkind, Zvi Nevo